{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:57:59Z","timestamp":1794225479545,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L022575\/1"],"award-info":[{"award-number":["MR\/L022575\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The types of outcomes measured collected in clinical studies and those required for cost-effectiveness analysis often differ. Decision makers routinely use quality adjusted life years (QALYs) to compare the benefits and costs of treatments across different diseases and treatments using a common metric. QALYs can be calculated using preference-based measures (PBMs) such as EQ-5D-3L, but clinical studies often focus on objective clinician or laboratory measured outcomes and non-preference-based patient outcomes, such as QLQ-C30. We model the relationship between the generic, preference-based EQ-5D-3L and the cancer specific quality of life questionnaire, QLQ-C30 in patients with breast cancer. This will result in a mapping that allows users to convert QLQ-C30 scores into EQ-5D-3L scores for the purposes of cost-effectiveness analysis or economic evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We use data from a randomized trial of 602 patients with HER2-positive advanced breast cancer provided 3766 EQ-5D-3L observations. Direct mapping using adjusted, limited dependent variable mixture models (ALDVMM) is compared to a random effects linear regression and indirect mapping using seemingly unrelated ordered probit models. EQ-5D-3L was estimated as a function of the summary scales of the QLQ-C30 and other patient characteristics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A four component mixture model outperformed other models in terms of summary fit statistics. A close fit to the observed data was observed across the range of disease severity. Simulated data from the model closely aligned to the original data and showed that mapping did not significantly underestimate uncertainty. In the simulated data, 22.15% were equal to 1 compared to 21.93% in the original data. Variance was 0.0628 in the simulated data versus 0.0693 in the original data. The preferred mapping is provided in Excel and Stata files for the ease of users.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A four component adjusted mixture model provides reliable, non-biased estimates of EQ-5D-3L from the QLQ-C30, to link clinical studies to economic evaluation of health technologies for breast cancer. This work adds to a growing body of literature demonstrating the appropriateness of mixture model based approaches in mapping.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08964-5","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:03:20Z","timestamp":1637233400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6365-7710","authenticated-orcid":false,"given":"Laura A.","family":"Gray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hernandez Alava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan J.","family":"Wailoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"issue":"1","key":"8964_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-10-151","volume":"10","author":"SH Kim","year":"2012","unstructured":"Kim SH, Jo MW, Kim HJ, Ahn JH. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes. 2012;10(1):1\u20136. https:\/\/doi.org\/10.1186\/1477-7525-10-151.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"8964_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12955-014-0180-6","volume":"12","author":"YB Cheung","year":"2014","unstructured":"Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group\u2019s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Heal Qual Life Outcomes. 2014;12(1):180. https:\/\/doi.org\/10.1186\/s12955-014-0180-6.","journal-title":"Heal Qual Life Outcomes"},{"issue":"4","key":"8964_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10198-010-0233-7","volume":"11","author":"R Crott","year":"2010","unstructured":"Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ. 2010;11(4):427\u201334. https:\/\/doi.org\/10.1007\/s10198-010-0233-7.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"8964_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40258-018-0404-8","volume":"16","author":"CF Lee","year":"2018","unstructured":"Lee CF, Ng R, Luo N, Cheung YB. Development of conversion functions mapping the FACT-B Total score to the EQ-5D-5L utility value by three linking methods and comparison with the ordinary Least Square method. Appl Heal Econ Heal Policy. 2018;16(5):685\u201395. https:\/\/doi.org\/10.1007\/s40258-018-0404-8.","journal-title":"Appl Heal Econ Heal Policy"},{"issue":"12","key":"8964_CR5","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jval.2018.06.006","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping. Value Heal. 2018;21(12):1399\u2013405.","journal-title":"Value Heal"},{"issue":"2","key":"8964_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s41669-017-0040-5","volume":"2","author":"M Rose","year":"2017","unstructured":"Rose M, Rice S, Craig D. Does methodological guidance produce consistency? A review of methodological consistency in breast Cancer utility value measurement in NICE single technology appraisals. PharmacoEconomics - Open. 2017;2(2):97\u2013107. https:\/\/doi.org\/10.1007\/s41669-017-0040-5.","journal-title":"PharmacoEconomics - Open"},{"issue":"4","key":"8964_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2015.02.016","volume":"18","author":"A Wailoo","year":"2015","unstructured":"Wailoo A, Hern\u00e1ndez M, Philips C, Brophy S, Siebert S. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Heal. 2015;18(4):425\u201331. https:\/\/doi.org\/10.1016\/j.jval.2015.02.016.","journal-title":"Value Heal"},{"issue":"7","key":"8964_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/0272989X13500720","volume":"34","author":"M Hernandez Alava","year":"2014","unstructured":"Hernandez Alava M, Wailoo A, Wolfe F, Michaud K. A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Mak. 2014;34(7):919\u201330. https:\/\/doi.org\/10.1177\/0272989X13500720.","journal-title":"Med Decis Mak"},{"issue":"6","key":"8964_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jval.2017.09.017","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray LA, Hern\u00e1ndez Alava M, Wailoo AJ. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma. Value Heal. 2018;21(6):748\u201357.","journal-title":"Value Heal"},{"issue":"3","key":"8964_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11136-012-0189-4","volume":"22","author":"H Dakin","year":"2013","unstructured":"Dakin H, Gray A, Murray D. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford knee score. Qual Life Res. 2013;22(3):683\u201394. https:\/\/doi.org\/10.1007\/s11136-012-0189-4.","journal-title":"Qual Life Res"},{"key":"8964_CR11","unstructured":"EORTC Quality of Life. EORTC QLQ-C30 Scoring Manual, 3rd Edition. 2001. Available at https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf. ISBN 2-9300 64-22-6."},{"issue":"7","key":"8964_CR12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11136-011-0037-y","volume":"21","author":"EJ Kim","year":"2012","unstructured":"Kim EJ. K KS, Kang HY. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Qual Life Res. 2012;21(7):1193\u2013203. https:\/\/doi.org\/10.1007\/s11136-011-0037-y.","journal-title":"Qual Life Res"},{"issue":"5","key":"8964_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/rheumatology\/kes400","volume":"52","author":"M Hern\u00e1ndez Alava","year":"2013","unstructured":"Hern\u00e1ndez Alava M, Wailoo A, Wolfe F, Michaud K. The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatol (UK). 2013;52(5):944\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/kes400.","journal-title":"Rheumatol (UK)"},{"issue":"9","key":"8964_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Heal Technol Assess. 2014;18(9):1\u2013224. https:\/\/doi.org\/10.3310\/hta18090.","journal-title":"Heal Technol Assess"},{"issue":"7","key":"8964_CR15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/0272989X15587497","volume":"35","author":"TA Young","year":"2015","unstructured":"Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping Functions in Health-Related Quality of Life: Mapping From Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. Med Decis Making. 2015;35(7):912\u201326. https:\/\/doi.org\/10.1177\/0272989X15587497.","journal-title":"Med Decis Making"},{"issue":"1","key":"8964_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non\u2013preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Heal [Internet]. 2017;20(1):18\u201327. Available from:. https:\/\/doi.org\/10.1016\/j.jval.2016.11.006.","journal-title":"Value Heal [Internet]"},{"key":"8964_CR17","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez Alava M, Wailoo AJ, Pudney S, Gray LA, Manca A. Mapping clinical outcomes to generic preference-based outcome measures : development and comparison of methods. Heal Technol Assess J [Internet]. 2020;24(34) Available from:. https:\/\/doi.org\/10.3310\/hta24340.","DOI":"10.3310\/hta24340"},{"issue":"8","key":"8964_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1177\/0272989X18797588","volume":"38","author":"F Woodcock","year":"2018","unstructured":"Woodcock F, Doble B. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L : an assessment of existing and newly developed algorithms. Med Decis Mak. 2018;38(8):954\u201367. https:\/\/doi.org\/10.1177\/0272989X18797588.","journal-title":"Med Decis Mak"},{"issue":"7","key":"8964_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, Kim S, Gonzalez-Martin A, LoRusso PM, Ferrero J, Smitt M, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(14)70178-0.","journal-title":"Lancet Oncol"},{"issue":"5","key":"8964_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"82","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst. 1993;82(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"14","key":"8964_CR21","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","volume":"36","author":"K Bjordal","year":"2000","unstructured":"Bjordal K, De Graeff A, Fayers P, Hammerlid E, Van Pottelsberghe C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck Cancer specific module (EORTC QLQ-H & N35) in head and neck patients. Eur J Cancer. 2000;36(14):1796\u2013807. https:\/\/doi.org\/10.1016\/S0959-8049(00)00186-6.","journal-title":"Eur J Cancer"},{"issue":"11","key":"8964_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"issue":"3","key":"8964_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","volume":"15","author":"M Hern\u00e1ndez Alava","year":"2012","unstructured":"Hern\u00e1ndez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Heal. 2012;15(3):550\u201361. https:\/\/doi.org\/10.1016\/j.jval.2011.12.014.","journal-title":"Value Heal."},{"issue":"1","key":"8964_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1477-7525-12-37","volume":"12","author":"A Wailoo","year":"2014","unstructured":"Wailoo A, Hernandez Alava M, Escobar MA. Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. Health Qual Life Outcomes. 2014;12(1):37. https:\/\/doi.org\/10.1186\/1477-7525-12-37.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"8964_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1536867X1501500307","volume":"15","author":"M Hernandez Alava","year":"2015","unstructured":"Hernandez Alava M, Wailoo AJ. Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata J. 2015;15(3):737\u201350. https:\/\/doi.org\/10.1177\/1536867X1501500307.","journal-title":"Stata J"},{"key":"8964_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A. Quality of life research within the EORTC\u2014the EORTC QLQ-C30. Eur J Cancer. 2002;38:125\u201333. https:\/\/doi.org\/10.1016\/S0959-8049(01)00448-8.","journal-title":"Eur J Cancer"},{"issue":"4","key":"8964_CR27","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s11136-015-1116-2","volume":"25","author":"B Doble","year":"2016","unstructured":"Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L : assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25(4):891\u2013911. https:\/\/doi.org\/10.1007\/s11136-015-1116-2.","journal-title":"Qual Life Res"},{"issue":"1","key":"8964_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jval.2016.09.2398","volume":"20","author":"G Fuller","year":"2017","unstructured":"Fuller G, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the Glasgow outcome scale following traumatic brain injury: a systematic review and mapping study. Value Heal. 2017;20(1):141\u201351.","journal-title":"Value Heal"}],"updated-by":[{"DOI":"10.1186\/s12885-022-09226-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08964-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08964-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T08:03:08Z","timestamp":1643270588000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08964-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8964"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08964-5","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-022-09226-8","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"28 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-022-09226-8","URL":"https:\/\/doi.org\/10.1186\/s12885-022-09226-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TH3RESA trial obtained independent ethical approval for the conduct of the study and subsequent use of anonymised data for research purposes from the institutional review boards covering 146 study sites in 22 countries. All patients provided written informed consent. TH3RESA was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable local laws. The data were made available for use in this study by F. Hoffman La Roche and were used under license. Data were fully anonymised, non-identifiable and accessed according to Roche\u2019s policy and process for clinical study data sharing.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Data is anonymised.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1237"}}